Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI).
Feliu J, Potter V, Grimaldi F, Clay J, Floro L, Saha C, Barber L, Orti G, Alnagar AA, Garcia-Muñoz R, Kenyon M, Krishnamurthy P, de Lavallade H, Raj K, McLornan D, Pagliuca A, Mufti GJ. Feliu J, et al. Among authors: potter v. Bone Marrow Transplant. 2020 Mar;55(3):562-569. doi: 10.1038/s41409-019-0695-x. Epub 2019 Sep 26. Bone Marrow Transplant. 2020. PMID: 31558789
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A. Marsh JC, et al. Among authors: potter v. Blood. 2011 Aug 25;118(8):2351-7. doi: 10.1182/blood-2010-12-327536. Epub 2011 Apr 25. Blood. 2011. PMID: 21518925 Free article. Clinical Trial.
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ. Krishnamurthy P, et al. Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21. Biol Blood Marrow Transplant. 2013. PMID: 23266740 Free article.
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ. Potter VT, et al. Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8. Biol Blood Marrow Transplant. 2014. PMID: 24216184 Free article.
Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.
Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P. Raj K, et al. Among authors: potter v. Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18. Biol Blood Marrow Transplant. 2014. PMID: 24650678 Free PMC article.
Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.
Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A, Yallop D, McMillan A, Ingram W, Khan A, Kenyon M, Potter V, Russell N, Mufti GJ, Pagliuca A. Noriega V, et al. Among authors: potter v. Leuk Res. 2014 Jul;38(7):737-43. doi: 10.1016/j.leukres.2014.03.005. Epub 2014 Mar 18. Leuk Res. 2014. PMID: 24787231
408 results